Novartis says 82 percent of leukemia patients in remission after CAR-T

(Reuters) - An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

This study used a nested qualitative longitudinal design with a convenience sample. Qualitative data were collected using semistructured interviews, and participants were invited to maintain journals. The semistructured interviews were audiotaped, transcribed, and loaded into Atlas.ti for analysis. Common themes and categories were verified and used to disseminate the findings. Seven YAs, mean age 32 (SD, 4) years, participated in this study. Three thematic classifications emerged: getting through, supported yet isolated, and information exchange preferences, which detail how these YAs processed and coped during treatment....
Source: Journal of Hospice and Palliative Nursing - Category: Nursing Tags: Feature Articles Source Type: research
ppe Rossi Considerable progress has been made in the treatment of acute myeloid leukemia (AML). However, current therapeutic results are still unsatisfactory in untreated high-risk patients and poorer in those with primary refractory or relapsed disease. In older patients, reluctance by clinicians to treat unfit patients, higher AML cell resistance related to more frequent adverse karyotype and/or precedent myelodysplastic syndrome, and preferential involvement of chemorefractory early hemopoietic precursors in the pathogenesis of the disease further account for poor prognosis, with median survival lower than six month...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
We report that the bone marrow stromal cell senescence is driven by p16INK4a expression. The p16INK4a-expressing senescent stromal cells then feedback to promote AML blast survival and proliferation via the SASP. Importantly, selective elimination of p16INK4a-positive senescent bone marrow stromal cells in vivo improved the survival of mice with leukemia. Next, we find that the leukemia-driven senescent tumor microenvironment is caused by AML induced NOX2-derived superoxide. Finally, using the p16-3MR mouse model we show that by targeting NOX2 we reduced bone marrow stromal cell senescence and consequently reduced A...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
This study shows the incidence of cancer associated with obesity has been rising dramatically in groups of individuals born in more recent decades,” said MD Anderson Cancer Center’s Dr. George Chang, who was not associated with the analysis. However, Chang warns against overgeneralizing on the basis of an epidemiological study. “The study was not set up to establish causation,” Chang said. “We know there are many factors that are associated with both obesity and cancer, such as lack of exercise and poor diet. How much each of those factors contribute to cancer is less clear.” Obesity is ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Cancer CNN Millennials Source Type: news
Chimeric Antigen Receptor T-cell (CAR-T) Immunotherapy was approved by the FDA in 2017 for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL), as well as adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. CAR-T immunotherapy uses a patient's own T cells and modifies them in a laboratory to recognize and kill the patient's cancer. Since the CAR-T modified cells multiply and persist in the patient's bloodstream, they have the potential to protect the patient against recurrence.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: 501 Source Type: research
Condition:   Acute Myeloid Leukemia Interventions:   Drug: Quizartinib;   Drug: Intrathecal (IT) triple chemotherapy prophylaxis;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Daunorubicin Sponsors:   Daiichi Sankyo, Inc.;   Innovative Therapies For Children with Cancer Consortium;   Children's Oncology Group Recruiting
Source: - Category: Research Source Type: clinical trials
Leukemia is the most common cancer among children and young adults and an increasing number of affected patients can expect a full recovery. The purpose of this study was to determine the prevalence of leukemia survivors among pregnant women and to examine pregnancy outcomes in this population.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Poster Session IV Source Type: research
Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess&nbs...
Source: - Category: Research Source Type: clinical trials
ConclusionsIn our population based analysis, we show that although the OS of t-AML is significantly worse than primary AML, those t-AML diagnosed and treated in recent years (2006-2015) had significantly better survival compared to earlier treatment periods. Among all primaries, outcomes of t-AML particularly following lung cancers are dismal compared to other primaries.DisclosuresGerds: Celgene: Consultancy; Apexx Oncology: Consultancy; CTI Biopharma: Consultancy; Incyte: Consultancy. Nazha: MEI: Consultancy. Carraway: FibroGen: Consultancy; Jazz: Speakers Bureau; Balaxa: Membership on an entity's Board of Directors or ad...
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Poster I Source Type: research
UCLA Health has joined an important national clinical trial that uses genetic testing to match people who have acute myeloid leukemia, or AML, with new therapies. UCLA ’s hospital system is the first in California to offer people the opportunity to participate.The Beat AML Master Trial will evaluate a precision-based medicine approach to treating the disease; it will allow people with the disease to have immediate access to new treatments that are currently in development without having to try more traditional approaches first. The approach could streamline a patient ’s course of treatment and, ultimately, save...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Cancer in Adolescents | Cancer in Young Adults | Cancer Therapy | Children | Health | Leukemia